Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)

• Published in: International journal of cardiology 2024-05, Vol.402, p.131819-131819, Article 131819
• Main Authors: Al-Yafeai, Zaki, Sondhi, Manush, Vadlamudi, Kavya, Vyas, Rahul, Nadeem, Daniyal, Alawadi, Mohammed, Carvajal-González, Alexander, Ghoweba, Mohamed, Ananthaneni, Anil
• Format: Article
• Language: English
• Subjects: CAD; Pericarditis; Psoriasis
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2024.131819

Psoriasis is a chronic skin condition characterized by hyperproliferation of epidermal keratinocytes, resulting in erythematous and scaling lesions. The US Food and Drug Administration (FDA) has approved nine biologic agents to address the burden of psoriasis, but their cardiovascular risks remain poorly studied. This retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) database to analyze adverse events associated with newly approved therapeutic agents for psoriasis. We employed disproportionally signal analysis, calculating the reporting odds ratio (ROR) with a 95% confidence interval. Among the vast FAERS database, which contained >25 million adverse events, a total of 334,399 events were associated with newly approved therapeutic agents for psoriasis. Cardiac adverse events accounted for 3852 cases, including pericarditis, atrial fibrillation, and coronary artery disease. Secukinumab had the highest number of reported adverse events, followed by brodalumab, while tildrakizumab had the lowest. Coronary artery disease was the most reported adverse event (1438 cases), followed by pericarditis (572 cases) and atrial fibrillation (384 cases). Secukinumab had the highest incidence of coronary artery disease, pericarditis, and atrial fibrillation. Risankizumab was significantly associated with an increased risk of coronary artery disease and atrial fibrillation, while tildrakizumab and Ixekizumab were associated with atrial fibrillation. Secukinumab was associated with an elevated risk of pericarditis. The study uncovers the cardiovascular adverse effects related to biologic agents used in psoriasis treatment. These findings emphasize the importance of monitoring and evaluating the cardiovascular safety profiles of biological agents used in psoriasis treatment. •Recently, the FDA has approved new psoriasis agents, but their cardiovascular profiles remain inadequately characterized.•Since 2015, FDA approved 9 psoriasis drugs; notable cardiotoxicity with risankizumab, tildrakizumab, secukinumab, ixekizumab•Coronary heart disease, pericarditis, and atrial fibrillation were the most prevalent cardiovascular complications reported.